骨化三醇治疗对2型糖尿病亚临床大血管病变的影响  

Effect of calcitriol on subclinical macrovascular disease in type 2 diabetic patients

作　　者：陈蕊华[1] 蒋晓真[1] 顾哲[1] 张渊[2] 顾佩莉[1] 周斌[1] 

机构地区：[1]上海市浦东新区人民医院内分泌科,201299 [2]上海市浦东新区人民医院超声科,201299

出　　处：《中华内分泌代谢杂志》2015年第3期251-253,共3页Chinese Journal of Endocrinology and Metabolism

基　　金：上海市卫生局青年科研项目（2010Y047）;上海市浦东新区优秀青年人才培养计划（PWRq2012439）

摘　　要：观察维生素D水平降低（〈30ng／m1）伴亚临床大血管病变的2型糖尿病患者使用骨化三醇治疗12个月后颈动脉内中膜厚度（cIMT）变化。86例患者分为治疗组（A组，n=44）与对照组（B组，n=42），A组使用骨化三醇干预（0．5μg／d），2组各40例完成随访。干预后，A组与B组比较，超敏C反应蛋白、可溶性CD36及cIMT显著降低，25一羟维生素D与踝肱指数显著升高（P〈0．05）。骨化三醇可改善维生素D缺乏的2型糖尿病伴亚临床大血管病变患者的cIMT。The changes of carotid intima media thickness （cIMT） in type 2 diabetic patients with vitamin D insufficiency and subclinical macrovascular disease after 12 months＇ intervention therapy with calcitriol were observed. 86 patients with vitamin D insufficiency [ 25 （OH） D〈30 ng/ml ] and subclinical macrovascular disease were randomized to group A （n = 44, treated with 0. 5 μg/day calcitriol） or group B （n = 42, blank control） for 12 months. 40 patients in each group completed the follow up. After 12 months of therapy with calcitriol （0.5 μg. qd. po. ）, levels of high sensitive-Creactive protein, sCD36, and clMT were significantly decreased, while 25 （OH） D and ankle brachial index were significantly increased （P〈0.05） in group A, suggesting that calcitriol could improve cIMT in patients with vitamin D insufficiency and subclinical macrovascular disease.

关 键 词：糖尿病 2型 亚临床大血管病变 骨化三醇 颈动脉内中膜厚度 

分 类 号：R587.2[医药卫生—内分泌]